BI 765128
Alternative Names: BI-765128Latest Information Update: 01 Sep 2023
At a glance
- Originator Boehringer Ingelheim
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Diabetic retinopathy
Most Recent Events
- 07 Aug 2023 Boehringer Ingelheim completes a phase-I/II clinical trials in Diabetic retinopathy in USA, Australia, Latvia, Netherlands, Spain, the UK (Intravitreous) (NCT04919499)
- 30 Jul 2021 Phase-I/II clinical trials in Diabetic retinopathy in USA (Intravitreous) (NCT04919499)
- 09 Jun 2021 Boehringer Ingelheim plans a phase I/II PARTRIDGE trial for Diabetic Retinopathy, in June 2021 [Intravitreous] (NCT04919499)